Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial

Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial

(1) The accuracy of patient-derived xenografts (PDXs) in predicting ADP-ribose polymerase inhibitor (PARPi) efficacy in ovarian cancer was tested, novel biomarkers were investigated, and whether PARPis could replace platinum-based chemotherapy as a first-line therapy was explored. (2) PDXs were reco...

Full description

Bibliographic Details
Main Authors: Jiayu Chen, Yan Li, Haiyuan Wang, Ting Li, Yu Gu, Wei Wang, Ying Shan, Jie Yin, Yongxue Wang, Meng Qin, Siyi Li, Lingya Pan, Siying Peng, Ying Jin
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
high-grade ovarian cancer
patient-derived xenograft
PARP inhibitor
precise medicine
Online Access:https://www.mdpi.com/2072-6694/14/19/4649

Similar Items

Similar Items